ProCE Banner Activity


FAQs: Current and Emerging Roles of BTK Inhibitors in MCL

Clinical Thought

In this commentary, expert faculty address frequently asked questions on the current and emerging roles of BTK inhibitors in the management of patients with MCL based on the latest data.

Physicians: maximum of 0.25 AMA PRA Category 1 CreditTM

Pharmacists: 0.25 contact hour (0.025 CEUs)

Registered Nurses: 0.25 Nursing contact hour and 0.2 pharmacology credits

Released: October 19, 2023

Expiration: October 18, 2024



Julie M. Vose

Julie M. Vose, MD, MBA

Newmann M. and Milde E. Harris Professor
Chief, Hematology/Oncology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Brad Kahl

Brad Kahl, MD

Professor of Medicine
Washington University in St. Louis
Director, Lymphoma Program
Siteman Cancer Center
St. Louis, Missouri

Provided by

This activity is developed with our educational partner, Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Lilly, and Merck Sharp & Dohme LLC.



Merck Sharp & Dohme, LLC


Clinical Care Options, LLC

ProCE Banner

Target Audience

This educational program is intended for hematologists, medical oncologists, nurses, pharmacists, and other HCPs who treat patients with MCL.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Mantle cell lymphoma (MCL)

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select optimal first-line treatment for patients with MCL who are not candidates for aggressive therapy

  • Develop BTK inhibitor‒based therapeutic strategies for patients with newly diagnosed MCL who are eligible for ASCT

  • Plan BTK inhibitor‒based therapeutic strategies for patients with R/R MCL, taking into consideration guideline recommendations, new indications, and recent practice-changing clinical trial results

  • Manage treatment-related symptoms in patients with MCL receiving BTK inhibitor‒based therapy to optimize adherence and clinical outcomes

  • Identify patients with MCL who may be eligible for ongoing clinical trials evaluating currently available and emerging BTK inhibitors and BTK inhibitor‒based combinations


Medical Learning Institute, Inc., is committed to providing high-quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Julie M. Vose, MD, MBA

Newmann M. and Milde E. Harris Professor
Chief, Hematology/Oncology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Julie M. Vose, MD, MBA: consultant/advisor/speaker: AbbVie.

Primary Author

Brad Kahl, MD

Professor of Medicine
Washington University in St. Louis
Director, Lymphoma Program
Siteman Cancer Center
St. Louis, Missouri

Brad Kahl, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Bristol Myers Squibb, Genentech, Janssen, Kite, Lilly, Merck, Novartis, Roche, Seagen.

All of the relevant financial relationships or individuals for this activity have been mitigated.

The planners and content peer reviewers from Medical Learning Institute, Inc., the accredited provider, and Clinical Care Options, LLC, the educational partner, do not have any relevant financial relationships to disclose with ineligible companies.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from October 19, 2023, through October 18, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Logo, company nameDescription automatically generatedIn support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and Clinical Care Options, LLC. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education

Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 0.25 contact hour and 0.2 contact hour in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 0.25 contact hour (0.025 CEU) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA0007322-0000-23-107-H01-P

Type of Activity: Knowledge

For Pharmacists, MLI will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: